Literature DB >> 25729739

The cis-AB01 allele originated from the A105 allele, and not from the A102 allele.

Sung-Jin Yang1, Eun Jeong Won1, Duck Cho2, Myung-Geun Shin2, Dong-Wook Ryang1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25729739      PMCID: PMC4330187          DOI: 10.3343/alm.2015.35.2.279

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


× No keyword cloud information.
Researchers in the field of transfusion medicine have a growing interest in the cis-AB blood group, which is characterized by a paradoxical inheritance of the ABO blood group [1]. The cis-AB blood group arises from a glycosyltransferase capable of synthesizing both A and B antigens simultaneously [2]. In addition, affected individuals display more than one phenotype depending on their partnering alleles. Cis-AB may eventually lead to ABO discrepancy [3]. The cis-AB allele was the most common ABO subgroup in Korean blood donors [4], and Cho et al. [5] found that the cis-AB allele was also the most common cause of ABO discrepancy in Koreans. From similar contexts, many authors have performed genetic analysis of cis-AB with sequencing methods for ABO genotyping. These studies have suggested that the cis-AB01 allele arises from a single polymorphism, 803G>C, in exon 7 of the A102 allele [6, 7]. However, the sequencing was solely focused on exons 6 and 7. According to a previous study, analysis of intron sequences indicated that individuals with the A102 allele may be re-classified into those with the A105 allele [8]. We therefore performed an extended analysis of the genomic sequences of the cis-AB01 allele, previously known as the A102 allele, to clarify its genetic background. Here, we screened five samples of the cis-AB01 allele through direct sequencing of exons 6 and 7 from samples submitted for ABO genotyping between January 2009 and December 2011 to Chonnam National University Hospital and Chonnam National University Hwasun Hospital. We performed ABO genotyping for all exons and introns except intron 1 and then compared the cis-AB01 and A101 allele sequences. This analysis showed identical point mutations in the cis-AB01, compared to A101 alleles (1142C>T in intron 4, 163T>C and 179C>T in intron 6, 467C>T and 803G>C in exon 7). We found only one nucleotide difference between the cis-AB01 allele and the A105 allele, 803G>C, in contrast to the three nucleotides that differed between the cis-AB01 and A102 alleles. Based on the prevailing hypothesis that mutations in the ABO gene render it capable of synthesizing both A and B antigens, our data led to the speculation that the A105 allele might have acquired a single point mutation at 803G>C in exon 7 and got converted to the cis-AB01 allele (Fig. 1). We found that the frequencies of the A101, A102, A105, O01, and O02 alleles were 3.3%, 33.3%, 23.3%, 20.0%, and 20.0%, respectively, in specimens (n=15) collected from individuals with the normal A phenotype. Thus, although A105 allele is the second most prevalent among A alleles, we assume that, without analysis of intron 6 sequences, the A105 allele can be mistaken for the A102 allele. Genetic analysis of exons 6 and 7 has been commonly used for demonstrating a new allele [6, 7, 9]; however, our results indicate that further studies are warranted to analyze lineage-specific variations in intron sequences, intron 6 in particular, which is essential for obtaining accurate results of the ABO genotyping. Moreover, we suggest performing intron analysis for the A105 allele in individuals from Southwestern Korea and Japan, both of which are predominant regions of the cis-AB allele.
Fig. 1

The molecular origin of the cis-AB01 allele is the A105 allele, but not the A102 allele. The cis-AB01 allele has five point mutations compared to the A101 allele as follows: 1142C>T in intron 4, 163T>C and 179C>T in intron 6, 467C>T and 803G>C in exon 7. The cis-AB01 allele has the only one nucleotide difference of 803G>C compared with the A105 allele.

Abbreviations: Ex, exon; Int, intron.

To the best of our knowledge, we have revealed the first complete genome sequence (except intron 1) of the cis-AB01 allele and shown that it arose from the A105 allele rather than the A102 allele. Our results are of significance in clarifying the phylogenetic and epidemiologic characteristics of the cis-AB01 allele.
  8 in total

1.  Unusual phenotype of cis-AB.

Authors:  D Cho; S-J Kee; J-H Shin; S-P Suh; D-W Ryang
Journal:  Vox Sang       Date:  2003-05       Impact factor: 2.144

2.  The serological and genetic basis of the cis-AB blood group in Korea.

Authors:  D Cho; S-H Kim; M-J Jeon; K-L Choi; S-J Kee; M-G Shin; J-H Shin; S-P Suh; M H Yazer; D-W Ryang
Journal:  Vox Sang       Date:  2004-07       Impact factor: 2.144

3.  A novel cis-AB allele derived from a unique 796C>A mutation in exon 7 of ABO gene.

Authors:  Cheng-Hwai Tzeng; Ying-Ju Chen; Jau-Yi Lyou; Pei-Shan Chen; Hsueng-Mei Liu; Hui-Yu Hu; Jeong-Shi Lin; Lung-Chih Yu
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157

Review 4.  A review of cis AB blood.

Authors:  H Yamaguchi
Journal:  Jinrui Idengaku Zasshi       Date:  1973-06

5.  Molecular genetic analysis of the ABO blood group system: 2. cis-AB alleles.

Authors:  F Yamamoto; P D McNeill; Y Kominato; M Yamamoto; S Hakomori; S Ishimoto; S Nishida; M Shima; Y Fujimura
Journal:  Vox Sang       Date:  1993       Impact factor: 2.144

Review 6.  The cis-AB blood group phenotype: fundamental lessons in glycobiology.

Authors:  Mark H Yazer; Martin L Olsson; Monica M Palcic
Journal:  Transfus Med Rev       Date:  2006-07

Review 7.  Sequence variation at the human ABO locus.

Authors:  S P Yip
Journal:  Ann Hum Genet       Date:  2002-01       Impact factor: 1.670

8.  [Resolution of ABO Discrepancies by ABO Genotyping.].

Authors:  Duck Cho; Jin Sol Lee; Ji Young Park; Mi Jeong Jeon; Jeong Won Song; Soo Hyun Kim; Myung Geun Shin; Jong Hee Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  Korean J Lab Med       Date:  2006-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.